NEJM has been parceling out the results of the ANNEXA studies like the Harry Potter movie series.  I can’t wait for the final verdict on Xa-inhibitor reversals and the subgroup analysis on intracranial bleeds.  But for now, here is the study methodology:


  • bolus over 15-30 minutes + 2-hour infusion
  • For Apixaban or Rivaroxaban >7h before
    • 400mg bolus, 480mg infusion
  • For Enoxaparin, Edoxaban, Rivaroxaban <7h before or unknown time
    • 800mg bolus, 960mg infusion


Anti–Factor Xa Activity and Percent Change from Baseline in Patients Receiving Rivaroxaban and Apixaban (Efficacy Population).




Subgroup Analysis:




Connolly, Stuart J. et al. “Andexanet Alfa For Acute Major Bleeding Associated With Factor Xa Inhibitors”. New England Journal of Medicine (2016).

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s